graf industrial corp is a blank check company. the company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. it intends to focus on industrial companies. it focuses on diversified industrial manufacturing, technology, distribution and service businesses, in the united states and canada.
Company profile
Ticker
NKGN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Graf Acquisition Corp. IV
SEC CIK
Corporate docs
Subsidiaries
NKGen Operating Biotech, Inc. ...
NKGN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
24 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
8-K
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
11 Apr 24
8-K
Entry into a Material Definitive Agreement
5 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
27 Mar 24
8-K
Other Events
20 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Feb 24
Latest ownership filings
4
Kathleen D. Scott
14 Feb 24
4
Yong Man Kim
14 Feb 24
4
Paul Y. Song
14 Feb 24
4
Pierre Gagnon
14 Feb 24
4
Michael Klowden
14 Feb 24
SC 13G
METEORA CAPITAL, LLC
14 Feb 24
SC 13G/A
Radcliffe Capital Management, L.P.
14 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13D/A
NKMAX Co., Ltd.
19 Dec 23
4
Sangwoo Park
15 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.04 mm | 9.04 mm | 9.04 mm | 9.04 mm | 9.04 mm | 9.04 mm |
Cash burn (monthly) | (no burn) | (no burn) | 11.06 mm | 3.65 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 76.42 mm | 25.19 mm | n/a | n/a |
Cash remaining | n/a | n/a | -67.38 mm | -16.16 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | -6.1 | -4.4 | n/a | n/a |
Institutional ownership, Q4 2023
64.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 5 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 10.60 bn |
Total shares | 14.76 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
NKMAX | 12.15 mm | $44.60 mm |
Meteora Capital | 1.60 mm | $4.39 bn |
University Of Chicago | 550.00 k | $1.51 bn |
Sandia Investment Management | 442.62 k | $4.61 bn |
NTRS Northern Trust | 15.72 k | $43.24 mm |
WFC Wells Fargo & Co. | 47.00 | $129.00 k |
Proequities | 0.00 | $0.00 |
Adage Capital Partners GP, L.L.C. | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Feb 24 | Kathleen D. Scott | Stock Option Common Stock | Grant | Acquire A | No | No | 1.62 | 300,000 | 486.00 k | 300,000 |
12 Feb 24 | Yong Man Kim | Stock Option Common Stock | Grant | Acquire A | No | No | 1.62 | 75,000 | 121.50 k | 75,000 |
12 Feb 24 | Paul Y. Song | Stock Option Common Stock | Grant | Acquire A | No | No | 1.62 | 1,260,000 | 2.04 mm | 1,260,000 |
12 Feb 24 | Pierre Gagnon | Stock Option (right to buy Common Stock | Grant | Acquire A | No | No | 1.62 | 360,000 | 583.20 k | 360,000 |
12 Feb 24 | Michael Klowden | Stock Option Common Stock | Grant | Acquire A | No | No | 1.62 | 300,000 | 486.00 k | 300,000 |
News
12 Health Care Stocks Moving In Friday's Intraday Session
26 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
23 Apr 24
What's Going On With Nano-Cap NKGen Biotech Stock On Monday?
22 Apr 24
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
22 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
19 Apr 24
Press releases
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
25 Apr 24
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
11 Apr 24
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference
25 Mar 24
Thinking about buying stock in Skywater Technology, Orion Group, NKGen Biotech, Porch Group, or AeroVironment?
11 Mar 24